Clinical Trials Logo

Clinical Trial Summary

Core myopathies (CCD/MmD), nemaline myopathies (NEM) and centronuclear myopathies (CNM) are three types of rare congenital myopathies. Not much is known about the natural history and no curative treatment is available for these groups. Also patients report fatigability as one of their symptoms. The goal of this observational study is to study the natural history during 24 months to achieve trial readiness and to study the muscle fatigability in CCD/MmD, NEM and CNM.


Clinical Trial Description

Rationale: Patients with CCD/MmD, NEM and CNM report symptoms of weakness in the arms and legs. Other symptoms include weakness of the respiratory, facial and swallowing muscles. No treatments are available for congenital myopathies (CM) to slow down or cure the disease. A few type I-II trials have taken place and more are expected. Therefore it is important to reach trial readiness. To create trial readiness, there is a need for natural history study to create a detailed report of the disease course and a selection of the most sensitive clinical and functional outcome measures and biomarkers. Besides muscle weakness, several patients report muscle fatigability. This has not been investigated systematically in CM. The lack of evidence calls for a cross-sectional study assessing muscle fatigability and neuromuscular transmission in CM. Objectives: i) To assess the natural disease course of CCD/MmD, NEM and CNM during 24 months. ii) To select relevant and sensitive clinical and functional outcome measures and biomarkers. iii) To assess the severity of muscle fatigability in CCD/MmD, NEM and CNM. Study design: Patients with a genetically confirmed CCD/MmD, NEM or CNM will be able to participate in this study. The study consist of 2 parts. Part 1: a prospective cohort study with 5 visits every 6 months, for a total of 2 years. 45 patients will be included for this part. Part 2: an observational study with 2 visits. For this part 75 patients will be included. There will be an overlap in patients for the two parts. So a total of approximately 100 patients will be included. A large set of tests will be performed to assess the full capabilities of the patient, e.g. muscle strength/endurance, muscle imaging (MRI/ultrasound), activities, walking ability, quality of life, muscle fatigability and the feeling of fatigue. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06157268
Study type Observational
Source Radboud University Medical Center
Contact Nicol Voermans, MD PhD
Phone +31650155770
Email Nicol.Voermans@radboudumc.nl
Status Not yet recruiting
Phase
Start date December 2023
Completion date November 2026

See also
  Status Clinical Trial Phase
Withdrawn NCT04977648 - Natural History Study of Patients With Centronuclear Myopathies
Enrolling by invitation NCT05099107 - Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment N/A
Completed NCT03351270 - Prospective Natural History Study of Patients With Myotubular Myopathy and Other CentroNuclear Myopathies N/A
Recruiting NCT04064307 - Myotubular and Centronuclear Myopathy Patient Registry
Recruiting NCT05982119 - Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study N/A
Terminated NCT04033159 - Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies Phase 1/Phase 2
Withdrawn NCT04743557 - Early Phase Human Drug Trial to Investigate DYN101 in Participants 2 to 17 Years With Centronuclear Myopathies Phase 1/Phase 2
Recruiting NCT00272883 - Molecular and Genetic Studies of Congenital Myopathies